GlassScriptPhysician profile
Wyche Coleman
NPI 1841491826
$35,103.84
in general payments reported to CMS, 2019-2025
25 companies · $6,182 in 2025
The $6,182 reported for 2025 was more than what 94% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $3,324 · 2021: $972 · 2022: $884 · 2023: $5,462 · 2024: $17K · 2025: $6,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $4,045 · Travel and Lodging: $520 · Gift: $36.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $24,500.00 |
| Food and Beverage | $4,044.63 |
| Travel and Lodging | $520.00 |
| Gift | $36.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Research LLC | $22,450.00 | 2020-2025 | |
| Alcon Vision LLC | $8,466.97 | 2019-2025 | Ngenuity, Clareon, Hydrus Microstent |
| Glaukos Corporation | $807.80 | 2019-2025 | Idosetr, Kxl1b-Ce-Marked Kxlsystem, Kxl System (Not Refurbished) |
| Biotissue Holdings INC. | $623.21 | 2021-2025 | |
| Sight Sciences, INC. | $505.60 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $352.82 | 2020-2021 | |
| Abbvie INC. | $290.48 | 2022-2025 | Lumigan, Durysta |
| Oyster Point Pharma, INC. | $277.58 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rxsight INC | $269.72 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $183.71 | 2019-2023 | |
| Lensar, INC. | $125.03 | 2025 | Lensar Laser System |
| Kala Pharmaceuticals, INC. | $124.46 | 2021 | |
| Aerie Pharmaceuticals, INC. | $114.91 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $99.57 | 2024-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Horizon Therapeutics Plc | $85.77 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $75.52 | 2019 | |
| New World Medical,INC. | $55.93 | 2021-2023 | |
| Carl Zeiss Meditec USA, INC. | $36.07 | 2025 | Visumax |
| Johnson & Johnson Surgical Vision, INC. | $33.28 | 2021-2024 | Tecnis Simplicity |
| Ocular Therapeutix, INC. | $28.29 | 2024-2025 | Dextenza |
| Mallinckrodt Hospital Products INC. | $22.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.23 | 2025 | Cobenfy |
| Lilly USA, LLC | $19.36 | 2020 | |
| Shire North American Group INC | $17.79 | 2019 | |
| Averitas Pharma INC. | $16.90 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wyche Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.